Abstract
A main feature of Fabry disease is nephropathy, with polyuria an early manifestation; however, the mechanism that underlies polyuria and affected tubules is unknown. To increase globotriaosylceramide (Gb3) levels, we previously crossbred asymptomatic Glatm mice with transgenic mice that expressed human Gb3 synthase (A4GALT) and generated the GlatmTg(CAG-A4GALT) symptomatic Fabry model mice. Additional analyses revealed that these mice exhibit polyuria and renal dysfunction without remarkable glomerular damage. In the present study, we investigated the mechanism of polyuria and renal dysfunction in these mice. Gb3 accumulation was mostly detected in the medulla; medullary thick ascending limbs (mTALs) were the most vacuolated tubules. mTAL cells contained lamellar bodies and had lost their characteristic structure (i.e., extensive infolding and numerous elongated mitochondria). Decreased expression of the major molecules—Na+-K+-ATPase, uromodulin, and Na+-K+-2Cl− cotransporter—that are involved in Na+ reabsorption in mTALs and the associated loss of urine-concentrating ability resulted in progressive water- and salt-loss phenotypes. GlatmTg(CAG-A4GALT) mice exhibited fibrosis around mTALs and renal dysfunction. These and other features were consistent with pathologic findings in patients with Fabry disease. Results demonstrate that mTAL dysfunction causes polyuria and renal impairment and contributes to the pathophysiology of Fabry nephropathy.—Maruyama, H., Taguchi, A., Nishikawa, Y., Guili, C., Mikame, M., Nameta, M., Yamaguchi, Y., Ueno, M., Imai, N., Ito, Y., Nakagawa, T., Narita, I., Ishii, S. Medullary thick ascending limb impairment in the GlatmTg(CAG-A4GALT) Fabry model mice.
Keywords: polyuria, mitochondria-rich cell, uromodulin, Na+-K+-2Cl− cotransporter, Na+-K+-ATPase
Fabry disease is an X-linked hereditary disease caused by mutations in GLA (α-galactosidase A) gene that encodes the lysosomal enzyme, GLA (1), and it is characterized by the systemic accumulation of glycosphingolipids, especially globotriaosylceramide (Gb3), in the lysosomes of various cell types (2). Approximately 750 GLA mutations have been identified to date (3). Fabry disease is categorized as classic or late onset, according to the presence or absence of early classic manifestations—acroparesthesia, clustered angiokeratoma, cornea verticillata, hypoanhidrosis, etc.—and the type of GLA mutation. Nephropathy is a main feature of both disease subtypes (4). The distribution of GLA in the normal human kidney varies according to cell type (5). Although it is absent in glomeruli and endothelial cells, it is highly expressed in all tubular segments and interstitial cells. Conspicuous podocyte vacuolization is highly pathognomonic, and podocyte injury is thought to play a critical role in the development and progression of Fabry nephropathy (6, 7). Progressive Gb3 deposition in the kidney results in proteinuria and the gradual deterioration of renal function and the development of azotemia (8), which affects all tubules, but especially the distal tubules for reasons that are unclear (9–11). No previous studies have used segment-specific Abs to clarify whether the affected segment is the thick ascending limb (TAL) or distal convoluted tubule (DCT) (9–11). Both glomerular and tubular injury occur in Fabry disease, and the effect of the latter alone on renal dysfunction is unclear.
Polyuria in Fabry disease was first reported in 1958 (12) and is prominent early in the disease course (6, 9, 12–16), although the affected tubules and underlying mechanism remain unknown (6, 13, 15, 16). Gla knockout (Glatm) mice do not develop Fabry disease as a result of a lesser accumulation of Gb3 than that observed in humans (17). To increase Gb3 levels, we previously crossbred asymptomatic Glatm mice (18, 19) with transgenic mice that expressed human Gb3 synthase (A4GALT) to generate the GlatmTg(CAG-A4GALT) symptomatic Fabry model mice. Additional analyses revealed that these mice exhibit polyuria and renal dysfunction without remarkable glomerular damage and provided the first clear evidence that Gb3 accumulation is the primary cause of Fabry disease (20). This mouse line is suitable for studying tubular injury that is directly caused by Gb3 accumulation. Autopsy specimens demonstrated Gb3 accumulation in the medullary TALs (mTALs) (21), which suggests that these are the most severely affected tubules. TAL plays critical roles in salt (Na+, K+, and Cl−) reabsorption, blood pressure (BP) control, urine concentration, and divalent cation (Ca2+ and Mg2+) homeostasis (22). We carried out the present study to clarify the mechanistic basis for polyuria and renal dysfunction in GlatmTg(CAG-A4GALT) mice and to examine TAL morphology in patients with Fabry nephropathy.
MATERIALS AND METHODS
Animal studies
Animals
The C57BL/6J-Glatm1kulTg(CAG-A4GALT) mouse line (20) was generated by crossbreeding C57BL/6J-Tg(CAG-A4GALT) mice that harbored the A4GALT transgene in a single allele with homozygous Gla knockout C57BL/6J;129S4-Glatm1kul mice (18). The following nomenclature is used hereafter to describe mouse models: Tg(A4GALT) for C57BL/6J-Tg(CAG-A4GALT), Glatm for C57BL/6J;129S4-Glatm1kul, and GlatmTg(A4GALT) for C57BL/6J-Glatm1kulTg(CAG-A4GALT). Wild-type (WT) mice (C57BL/6J) were purchased from Charles River Laboratories (Yokohama, Japan). All mice were housed under standard laboratory conditions of 24 ± 2°C and 50–60% humidity on a 12-h light/dark cycle with free access to tap water and commercial standard rodent chow that contained 1.20% calcium, 1.08% phosphate, and 240 IU/100 g vitamin D3 (CE-2; Clea Japan, Tokyo, Japan). Mouse lines were genotyped by PCR amplification of A4GALT as described in Taguchi et al. (20). To eliminate the possibility that the phenotype could be affected by pregnancy, female mice were excluded from experiments. All animal protocols were reviewed by the institutional animal care and use committee and were approved by the Presidents of Niigata University (H21 Niigata University Research 69, H25-111 Niigata University Research 255-1, H27-182 Niigata University Research 323-6) and Oita University (P006002).
Blood analysis
Na, K, Cl, glucose, blood urea nitrogen, and creatinine (Cr) levels in whole blood were determined by using an i-Stat analyzer (Abbott, Tokyo, Japan). Total protein, albumin, uric acid, Ca, and Mg levels were measured by the Oriental Yeast Co. (Nagahama, Japan). Plasma osmolality was calculated by using the following formula: osmolarity = 1.86 (Na + K) + glucose + urea + 10 [with Na, K, glucose (mM)] (23).
Urine analysis
Mice were maintained in metabolic cages for 24 h of urine collection. Urine Na, K, Cl, Ca, Mg, urea nitrogen, and Cr were analyzed by the Oriental Yeast Company. Urine osmolality was measured and the fractional excretion (FE) of a solute X (FEx) was calculated by using the following formula: FEx = ([X]24 h urine × 24 h urine volume)/([X] plasma × Cr clearance) × 100 (24). The level of 8-hydroxyl-2′-deoxyguanosine (8-OHdG) was measured by using the new 8-OHdG Check Eliza Kit (JaICA, Fukuroi, Japan).
Mouse kidney pathology
Kidneys were cut transversely and fixed in 10% neutral-buffered formalin, embedded in paraffin, and treated with periodic acid–Schiff (PAS) and elastica Masson trichrome stains. Deparaffinized sections were prepared by routine procedure. Immunohistochemical staining of formalin-fixed, paraffin-embedded kidneys was performed after antigen retrieval in Target Retrieval Solution (Dako, Glostrup, Denmark). Abs against the following proteins were used: uromodulin (UMOD; AbD Serotec, Raleigh, NC, USA), Na+-K+-2Cl− cotransporter (NKCC2; StressMarq Biosciences, Victoria, BC, Canada), Na+-K+-ATPase (Abcam, Cambridge, United Kingdom), F4/80 (AbD Serotec), Na+-Cl− cotransporter (NCC; EMD Millipore, Billerica, MA, USA), aquaporin-2 (AQP2; Abcam), and malondialdehyde (JaICA). All slides were counterstained with hematoxylin. We performed Gb3 staining with Shiga toxin 1 B subunit and transmission electron microscopy as described in Taguchi et al. (20). Toluidine blue staining was performed with 0.05% toluidine blue solution. We used an all-in-one fluorescence microscope (BZ-X700; Keyence, Osaka, Japan) to document staining. Information on Abs used in this study is provided in Supplemental Table 1.
Real-time RT-PCR analysis
Real-time RT-PCR was performed by using total RNA from the whole kidney along with appropriate primer sets and the One-Step SYBR PrimeScript Plus RT-PCR Kit (Takara Bio, Kusatsu, Japan) on a Thermal Cycler Dice Real Time System II (Takara Bio). Forward and reverse primer sequences used are as follows: glyceraldehyde 3-phosphate dehydrogenase (Gapdh): 5′-TGTGTCCGTCGTGGATCTGA-3′ and 5′-TTGCTGTTGAAGTCGCAGGAG-3′; Umod: 5′-GGTCCCTGTGGGACAGTATTGAG-3′ and 5′-GATGATCGCATTTGCCAGGTAG-3′; solute carrier family 12 member (Slc12a) 1: 5′-GATGCAGAACTGGAAGCAGTCAA-3′ and 5′-GCCATGTACAACAAATCCGAAATAG-3′; transforming growth factor β (Tgfb) 1: 5′-GTGTGGAGCAACATGTGGAACTCTA-3′ and 5′-CGCTGAATCGAAAGCCCTGTA-3′; collagen type I α 1 chain (Col1a1): 5′-GACATGTTCAGCTTTGTGGACCTC-3′ and 5′-GGGACCCTTAGGCCATTGTGTA-3′; collagen type III α 1 chain (Col3a1): 5′-CAGGCCAGTGGCAATGTAAAGA-3′ and 5′-CTCATTGCCTTGCGTGTTTGATA-3′; fibronectin (Fn) 1: 5′-GCTTTGGCAGTGGTCATTTCAG-3′ and 5′-ATTCCCGAGGCATGTGCAG-3′; C-C motif chemokine ligand (Ccl) 2: 5′-AGCAGCAGGTGTCCCAAAGA-3′ and 5′-GTGCTGAAGACCTTAGGGCAGA-3′; chemokine (C-X3-C motif) ligand (Cx3cl) 1: 5′-ATCCGCTATCAGCTAAACCAGGAG-3′ and 5′-TCCCAGGTGTCACATTGTCCA-3′; adhesion G protein-coupled receptor E (Adgre) 1: 5′-GAGATTGTGGAAGCATCCGAGAC-3′ and 5′-GACTGTACCCACATGGCTGATGA-3′; hepatocyte growth factor (Hgf): 5′-TCCATGTGGGACAAGAATATGGAG and 5′-CATCATCAGGATTCCGGCAGTA-3′; Slc12a3: 5′-TCGGCAGGTGAGACTGAGTGA-3′ and 5′-GTCTCCAGCCAGGCCATGTA-3′; and Aqp2: 5′-AGCTGGTGCTGTGCATCTTTG-3′ and 5′-ATGGAGCAGCCGGTGAAATA-3′. mRNA expression levels were calculated as the inverted cycle threshold relative to the level of Gapdh.
Western blot analysis
Whole-kidney homogenates were adjusted to the same protein concentrations as determined by the DC Protein Assay (Bio-Rad, Hercules, CA, USA). Abs against the following proteins were used: UMOD (AbD Serotec), NKCC2 (Alpha Diagnostic International, San Antonio, TX, USA), Na+-K+-ATPase (Abcam), NCC (EMD Millipore), AQP2 (Abcam), arginine vasopressin (AVP) receptor 2 (Alomone Labs, Jerusalem, Israel), and GAPDH (MilliporeSigma, St. Louis, MO, USA). Abs were diluted with Western Blot Immuno Booster (Takara Bio). Immunoreaction was detected with SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Waltham, MA, USA), and protein bands were scanned with an ImageQuant LAS 4000 Mini (GE Healthcare, Piscataway, NJ, USA) and quantified by using ImageQuant TL v.8.1 software (GE Healthcare). Information on the Abs used in this study is provided in Supplemental Table 1.
Other assays
Plasma AVP concentration was measured by using the Arg8-Vasopressin Chemiluminescent Immunoassay Kit (Arbor Assays, Ann Arbor, MI, USA). ATP concentration in kidneys was measured by using an ATP Assay Kit (Toyo Ink, Tokyo, Japan). BP—an average of 3 consecutive measurements—was measured with the tail-cuff method using a programmable sphygmomanometer (Softron, Tokyo, Japan). To eliminate the effect of environmental changes on BP, mouse handlers measured BP in a quiet rearing room. Vendor-derived WT mice were allowed to acclimate to the rearing environment for at least 1 wk upon arrival before measurements were taken. Each mouse was gently immobilized in a mouse holder and maintained at 39°C in the warmer >5 min before measurements were taken to allow the mouse to acclimate to the holder and to increase blood flow to the tail artery. As most mice adapted to measurements, there was no prior training. When a mouse did not remain quiet, BP was measured the next day or later.
Statistical analysis and graph preparation
At least 5 mice/group were used for all studies, except for histologic analyses. Two-tailed significance values are reported. We used the Shapiro–Wilk test to test for normal distribution. Normally distributed data were evaluated for variance with the F test. Statistical analyses—Student’s t test, Welch’s t test, and Wilcoxon rank-sum test—were performed using JMP v.12 (SAS Institute, Cary, NC, USA). Values of P < 0.05 were considered statistically significant. SigmaPlot v.12.5 (Systat Software, San Jose, CA, USA) was used to draw graphs.
Human studies
Informed consent and ethics
The study protocol was approved by the Ethics Committee of the Niigata University School of Medicine (H27-2137 and H28-2414) and the collaborating hospitals in accordance with the Declaration of Helsinki, and written informed consent was obtained from all patients.
Human kidney pathology
PAS and elastica Masson trichrome staining were performed as described above. Immunohistochemical staining was performed with the HRP-DAB System Cell and Tissue Staining Kit (R&D Systems, Minneapolis, MN, USA) and the above-mentioned primary Abs after antigen retrieval in Target Retrieval Solution. Toluidine blue staining and transmission electron microscopy were performed as described above with minor differences in reagents and devices. Information on Abs used is provided in Supplemental Table 2.
RESULTS
Gb3 accumulates in various renal tubules
To examine the global effect of Gb3 overload on kidneys, kidney sections were stained for Gb3 by using Shiga toxin 1 B subunit. In WT mice, the collecting duct (CD) area was positive for Gb3 (Fig. 1A), as previously reported (25). In GlatmTg(CAG-A4GALT) mice, staining progressively spread to and was enhanced in all tubules, except for many in the outer stripe (OS) (Fig. 1A). Differences in Gb3 accumulation between strains were mostly detected in the outer and inner medulla, which indicates that these areas were the main affected sites. Gb3 that were stained with toluidine blue in lysosomes (19) appeared as dots, especially in TALs and CDs in the outer and inner medulla (Fig. 1B). There was no staining in glomeruli. These data are consistent with the finding that Gb3 is not only present in lysosomes, but is also widely distributed in extralysosomal structures, even in the absence of lysosomal inclusions as observed in patients with Fabry disease (26).
Vacuolization predominantly appears in mTALs
Vacuolization of TAL in GlatmTg(CAG-A4GALT) mice was predominant in the inner stripe (IS), followed by the OS, and was sparse in the cortex of 5-wk-old mice with later progression (Fig. 1C–G). The nucleus and cytoplasm of TAL cells swelled, whereas the lumen narrowed with development (Fig. 1C–E). Cellular infiltration was prominent around impaired TALs (Fig. 1C–E). Some TAL cells were binuclear, which indicates regeneration (Fig. 1C–G). Vacuolization was absent from proximal tubules and glomeruli (Fig. 1F–H), and some CD cells were swollen (Fig. 1I). These observations suggest that, apart from the Gb3 overload, mTAL cells also possess certain other characteristics that contribute to the severe effect on mTALs.
TAL dysfunction induces water- and salt-loss phenotypes
GlatmTg(CAG-A4GALT) mice were characterized by progressive polyuria, polydipsia, and decreased urine osmolality (Fig. 2A), which indicates an inability to concentrate urine. Daily urinary excretion of solutes in GlatmTg(CAG-A4GALT) mice increased progressively (Fig. 2B). TAL reabsorbs Na+, K+, and Cl− via transepithelial transport and Ca2+ and Mg2+ via paracellular transport (22). FE is a parameter that reflects the tubular reabsorption of solutes; the FE of a solute X (FEx) expresses the amount of solute X that is excreted in the urine as a percentage of the amount of filtered X. A decrease in tubular reabsorption of X leads to high FEx. GlatmTg(CAG-A4GALT) mice displayed a higher FE of solutes than did WT mice by age 20 wk (Fig. 2C), which resulted in progressive water- and salt-loss phenotypes; all findings related to electrolytes could be attributed to TAL dysfunction (27). Water and salt loss affected the blood chemistry values of GlatmTg(CAG-A4GALT) mice (Fig. 2D) and led to progressive renal dysfunction (Fig. 2D). As expected, these mice had a lower BP than did WT mice by age 10 wk (Fig. 2E).
Decreased levels of UMOD, Umod, NKCC2, Slc12a1, and Na+-K+-ATPase in TALs
TAL cells in WT mice demonstrated extensive infolding and numerous elongated mitochondria (Fig. 3A) (28). In contrast, we observed lamellar bodies, round mitochondria, and disorganized, flattened infoldings in mTAL cells of GlatmTg(CAG-A4GALT) mice (Fig. 3A).
The TAL-specific protein, UMOD, facilitates membrane trafficking and NKCC2 protein function (29). In WT mice, UMOD was densely distributed in the IS (Fig. 3B), but was weakly expressed on the apical and basolateral membranes in the IS (Fig. 3C). The protein was sparsely distributed (Fig. 3B) but demonstrated a stronger signal in the OS and cortex (Fig. 3C). In GlatmTg(CAG-A4GALT) mice, UMOD expression was reduced in the outer medulla (IS > OS) by age 10 wk, with a progressive decrease in levels thereafter (Fig. 3B, C).
NKCC2 is important for Na+-Cl− reabsorption, which is required to maintain a high interstitial osmolality for countercurrent multiplication and water reabsorption by CDs as well as for divalent cation transport in TALs (27). In WT mice, NKCC2 was broadly distributed (Fig. 3D) and expressed in the apical domain of the TAL and macula densa (Fig. 3E); however, in GlatmTg(CAG-A4GALT) mice, levels were lower in the outer medulla (IS > OS) by age 10 wk and progressively decreased (Fig. 3D). NKCC2 expression persisted in the macula densa (Fig. 3E), which suggests that these cells retained normal function.
Na+-K+-ATPase, which mediates Na+ reabsorption, is highly expressed in the basolateral membrane of the highly Na+-reabsorbing nephrons, DCTs, and TALs (30). In WT mice, Na+-K+-ATPase distribution was dense in the IS and sparser in the OS and cortex (Fig. 3F), whereas, in TALs, there was high expression that clearly delineated cell morphology (Fig. 3G). In GlatmTg(CAG-A4GALT) mice, staining intensity was reduced in the IS, and the area with a lower signal progressively expanded (Fig. 3F, G), which indicates that impaired Na+ transport systems contribute to TAL dysfunction. This was supported by the observation that Umod mRNA and UMOD protein, Slc12a1 mRNA, and NKCC2 protein levels (Fig. 4A–D), along with Na+-K+-ATPase expression (Fig. 4E), were significantly lower in GlatmTg(CAG-A4GALT) mice compared with WT mice.
Fibrosis and inflammation are detected surrounding impaired TALs
Fibrosis is an early event in the course of Fabry nephropathy (31). In the tubular cytoplasm of GlatmTg(CAG-A4GALT) mice, elastica Masson trichrome staining became progressively weaker (Fig. 5A, B), which is similar to the gradual accumulation of Gb3. Focal fibrosis was detected around TALs in the outer medulla (IS > OS) of GlatmTg(CAG-A4GALT) mice by age 10 wk and progressed with age (Fig. 5A, B). Macrophage-specific antigen F4/80–positive cells infiltrated into and around TALs, then spread throughout the tissue in GlatmTg(CAG-A4GALT) mice (Fig. 5C, D). Transcript levels of the major fibrosis, inflammation, and regeneration markers were up-regulated (Fig. 5E).
Downstream tubular compensatory response to salt- and water-loss phenotypes induced by TAL dysfunction
Enhanced Na+ delivery to the DCT is thought to stimulate DCT hypertrophy as a compensatory response, which manifests as increases in mitochondrial size and infolding (32, 33). DCT cells had a broad apical cytoplasmic region with vesicles, but there were no increases in mitochondrial size and infolding in GlatmTg(CAG-A4GALT) mice (Fig. 6A). Thus, these mice demonstrated hypertrophy of DCT cells, but lacked some of its features (32, 33). NCC (Slc12a3) is a DCT-specific Na+-Cl− cotransporter that plays an important in fine-tuning Na+ excretion (34, 35). Slc12a3 mRNA and total NCC protein levels did not differ significantly between GlatmTg(CAG-A4GALT) and WT mice (Fig. 6B, C). NCC staining of the DCT revealed a wider lumen, increased cell size, and decreased cell density, which indicates hypertrophy (Fig. 6D), and not hyperplasia (36), of DCT cells. NCC-positive lumen surface area was greater and more prominent in GlatmTg(CAG-A4GALT) mice (Fig. 6D), which suggests a compensatory response. DCT cells are enriched in mitochondria and have the highest density of Na+-K+-ATPase in the kidney (30); Na+-K+-ATPase signals in DCT cells were similar between GlatmTg(CAG-A4GALT) and WT mice (Fig. 6E).
Both principal and mitochondria-rich intercalated cells in GlatmTg(CAG-A4GALT) mice displayed accumulation of lamellar bodies, but normal nuclei (Fig. 7A). AQP2 is a water channel that is responsible for water reabsorption in CDs (37). Aqp2 mRNA and AQP2 protein were up-regulated in GlatmTg(CAG-A4GALT) mice (Fig. 7B, C). Principal cells in the GlatmTg(CAG-A4GALT) medulla were swollen, but demonstrated normal AQP2 staining at the apical membrane and in the cytoplasm throughout the kidney (Fig. 7D). Although plasma AVP (Fig. 7E) levels in GlatmTg(CAG-A4GALT) and WT mice were not significantly different, they showed a higher trend in GlatmTg(CAG-A4GALT) mice. AVP receptor 2 (Fig. 7F) protein levels did not differ significantly between GlatmTg(CAG-A4GALT) and WT mice.
Oxidative stress and impaired energy metabolism
Oxidative stress plays an important role in the pathophysiology of Fabry disease (38). Malondialdehyde, a lipid oxidative stress marker, was detected in mTAL of GlatmTg(CAG-A4GALT) mice by age 10 wk (Fig. 8A). This coincided with changes in UMOD and NKCC2 expression (Fig. 3B, D) and renal injury (Fig. 2). Urinary excretion of 8-OHdG, a mitochondrial oxidative stress marker, progressively increased in GlatmTg(CAG-A4GALT) mice (Fig. 8B), which suggests that impaired mitochondria resulted in oxidative stress. Na+-K+-ATPase accounts for most of the energy consumption in the kidneys (39); we found that renal ATP content was similar between GlatmTg(CAG-A4GALT) and WT mice (Fig. 8C). The lower ATP production by impaired TAL mitochondria may have been offset by reduced ATP consumption that was a result of the down-regulation of Na+-K+-ATPase in TAL.
TAL impairment in patients with Fabry disease
We investigated TAL impairment in 9 patients with Fabry disease (Supplemental Table 3). Biopsied specimens that consisted of the cortex and medulla of 3 patients with non-Fabry chronic kidney disease served as control (Supplemental Table 4). In patients with Fabry disease (Fig. 9A, B), PAS staining revealed podocyte vacuolization that appeared as a lacy expanded cytoplasm, as described in Colvin (40). TAL and DCT vacuoles were pale. Tubular cytoplasm demonstrated weak elastica Masson trichrome staining, and collagen was abundant around vacuolated tubules, which indicates fibrosis. Vacuolated TAL cells were weakly positive or negative for UMOD immunoreactivity, whereas NKCC2 expression was attenuated in the apical membrane and cytoplasm. Na+-K+-ATPase was down-regulated in the basolateral membrane. The degree to which UMOD, NKCC2, and Na+-K+-ATPase expression was decreased in impaired TAL cells varied. AQP2 was weakly detected in the apical membrane and cytoplasm of principal cells, and vacuolization was prominent in swollen AQP2-negative intercalated cells in CDs, as previously reported (10). Although disease severity varied among patients, semiquantification of tubular impairment indicated that mTALs were most severely impaired, followed by DCTs and cortical TALs (Fig. 10). A comparison of the first biopsy (B) and a second biopsy performed 15 yr later (B2) demonstrated that mTAL (B) was more severely impaired than cortical TAL (B2).
TAL cells contained lamellar bodies (Fig. 9C, D); infolding was disorganized and confined to the basal side, and mitochondria were reduced in number and were smaller than normal. In CDs, mitochondria-rich intercalated cells exhibited mitochondrial abnormalities and contained lamellar bodies (Fig. 9E), which were also present in endothelial and smooth muscle cells of the microvasculature (Fig. 9C, F).
DISCUSSION
Using GlatmTg(CAG-A4GALT) Fabry model mice with polyuria, we have demonstrated that mTALs, especially in the IS, were the main tubules that were affected and that TAL dysfunction—an inability to concentrate urine—as a result of decreased expression of core molecules (Na+-K+-ATPase, UMOD, and NKCC2) induced water- and salt-loss phenotypes. Similar pathologic changes were observed in patients with Fabry disease. Given the critical roles played by TAL (22) and the resistance of distal tubules to enzyme replacement therapy (41), the identification of mTAL as the affected tubule in Fabry disease is significant.
mTALs may be targeted as a result of the characteristics of highly metabolic TAL cells (42), including their structure—extensive basolateral membrane and enrichment of mitochondria—and Na+ reabsorption function [Na+-K+-ATPase accounts for over 50% of energy consumed by the kidney (39)], and low medullary circulation (43, 44). As TALs of the IS are located outside the vascular bundles, their oxygen supply is limited, which makes them vulnerable to hypoxic injury (35). Gb3 accumulation in the microvasculature may affect luminal patency, inducing a proinflammatory and procoagulant response that leads to ischemic injury (40). The current study suggests that oxidative stress that results from mitochondrial impairment because of Gb3 accumulation and the limited blood supply in the IS (43) may synergistically affect TAL cells (45). Mitochondria-rich DCT cells (9–11) and intercalated cells (21) may be similarly affected.
TAL plays a critical role in the urine-concentrating mechanism. Na+-Cl− absorption by water-impermeable TAL dilutes the luminal fluid and drives the renal countercurrent multiplication system that generates the axial osmolality gradient in the outer medulla, thereby facilitating the absorption of water by the CD (18). Mitochondria-poor principal cells may be able to withstand Gb3 accumulation and up-regulate Aqp2 expression. Indeed, we found that they reacted to partially compensate for water loss caused by TAL dysfunction in GlatmTg(CAG-A4GALT) mice (Fig. 7A–D). Thus, water loss was not solely because of impaired CDs.
UMOD abundance in TAL, particularly in mTAL, was demonstrated to progressively decrease in Fabry disease (21). The level of UMOD expression was inversely proportional to the degree of lysosomal storage; it was suggested that abnormal UMOD expression in mTAL may contribute to the impaired urine-concentrating ability in Fabry disease. NKCC2 and UMOD in TAL contribute to the mechanism of polyuria. Loss-of-function mutations in SLC12A1 in humans (44) and Slc12a1 knockout in mice (46) lead to Bartter syndrome type I, and decreased levels of Umod are likely responsible for the polyuria observed in Umod knockout mice (47). We found that the down-regulation of 3 core molecules for Na+ reabsorption—Na+-K+-ATPase, UMOD, and NKCC2—contributed to the development of polyuria in GlatmTg(CAG-A4GALT) mice via impairment of TAL.
Gb3 is incorporated into the plasma membrane and intracellular membranes with a preference for lipid rafts (48). Alterations in lipid raft composition that were observed in Fabry disease induce changes in lipid raft dynamics (48). UMOD, NKCC2, and Na+-K+-ATPase are localized in lipid rafts. UMOD interacts with NKCC2 in apical trafficking (47, 49) and regulates the turnover, trafficking, and basolateral expression of Na+-K+-ATPase (50). TAL dysfunction in GlatmTg(CAG-A4GALT) mice may be caused, in part, by a decrease in these interactions.
The current study has several limitations. First, BP was not measured by the validated tail-cuff method (51), there was no training for the procedure, and fewer measurements were made. Moreover, compared with in-house mice, those mice that were obtained from vendors demonstrated a higher BP (52). Nonetheless, WT mice did not have high BP. Thus, BP values measured in this study may not differ significantly from those that would have been measured by the validated tail-cuff method. Overall, we believe that a difference in BP exists between GlatmTg(CAG-A4GALT) and WT mice. Second, although we evaluated NCC abundance by Western blot analysis, we did not examine the phosphorylation status of the protein (32), which is a more useful measure of activity.
Although tubular injuries have been observed early in the course of human Fabry disease (6, 9, 12–16, 41), it is unclear whether these injuries contribute to the development of end-stage renal disease. In GlatmTg(CAG-A4GALT) mice, mTAL injury that was directly caused by Gb3 accumulation, and not by podocyte injury, contributed to fibrosis, which led to renal dysfunction. It may therefore be important to note the occurrence of mTAL injury in addition to podocyte injury in human Fabry nephropathy.
In summary, we found that mTAL was the most severely affected tubule in our mouse model of Fabry disease with polyuria, and that TAL dysfunction—reduction in the levels of Na+-K+-ATPase, UMOD, and NKCC2—impairs the urine-concentrating ability. In addition, fibrosis associated with TAL impairment may be responsible for renal dysfunction. Results highlight the importance of mTAL dysfunction in the pathophysiology of Fabry nephropathy. Additional studies are required to verify whether our findings are relevant to the human disease and could provide a basis for the development of novel therapies.
Supplementary Material
This article includes supplemental data. Please visit http://www.fasebj.org to obtain this information.
ACKNOWLEDGMENTS
The authors thank Yoko Okada (Asahikawa Medical University), Keiko Yamagiwa, Akiko Seino, Kazumasa Sato, Kaori Takahashi (all from Niigata University Graduate School of Medical and Dental Sciences), Dr. Mitsutoshi Fukagawa (Joetsu General Hospital), and Kanako Oda (Brain Research Institute, Niigata University) for technical assistance. This work was supported by the Japan Society for the Promotion of Science (KAKENHI) Grant-in-Aid for Scientific Research (B) (JP 23390223; to H.M. and S.I.). H.M. has received research support from Sanofi (Tokyo, Japan). S.I. is an employee of and shareholder in GlycoPharma Corp. The remaining authors declare no conflicts of interest.
Glossary
- AQP2
aquaporin-2
- AVP
arginine vasopressin
- BP
blood pressure
- CD
collecting duct
- Cr
creatinine
- DCT
distal convoluted tubule
- FE
fractional excretion
- Gb3
globotriaosylceramide
- GLA
α-galactosidase A
- IS
inner stripe
- mTAL
medullary thick ascending limb
- NCC
Na+-Cl− cotransporter
- NKCC2
Na+-K+-2Cl− cotransporter
- 8-OHdG
8-hydroxyl-2′-deoxyguanosine
- OS
outer stripe
- PAS
periodic acid–Schiff
- Slc12
solute carrier family 12 member
- TAL
thick ascending limb
- UMOD
uromodulin
- WT
wild type
Footnotes
This article includes supplemental data. Please visit http://www.fasebj.org to obtain this information.
AUTHOR CONTRIBUTIONS
H. Maruyama and S. Ishii designed the study; H. Maruyama, A. Taguchi, Y. Nishikawa, C. Guili, M. Mikame, M. Nameta, M. Ueno, N. Imai, and S. Ishii performed experiments and analyzed data; Y. Yamaguchi, Y. Ito, T. Nakagawa, and I. Narita analyzed data; H. Maruyama and S. Ishii wrote the paper; and all authors contributed to the redrafting of the paper and agreed to its contents.
REFERENCES
- 1.Brady R. O., Gal A. E., Bradley R. M., Martensson E., Warshaw A. L., Laster L. (1967) Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N. Engl. J. Med. 276, 1163–1167 [DOI] [PubMed] [Google Scholar]
- 2.Kanda A., Nakao S., Tsuyama S., Murata F., Kanzaki T. (2000) Fabry disease: ultrastructural lectin histochemical analyses of lysosomal deposits. Virchows Arch. 436, 36–42 [DOI] [PubMed] [Google Scholar]
- 3.The Human Gene Mutation Database GLA. Available at: http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GLA. Accessed December 27, 2017
- 4.Desnick R. J., Banikazemi M., Wasserstein M. (2002) Enzyme replacement therapy for Fabry disease, an inherited nephropathy. Clin. Nephrol. 57, 1–8 [DOI] [PubMed] [Google Scholar]
- 5.Christensen E. I., Zhou Q., Sørensen S. S., Rasmussen A. K., Jacobsen C., Feldt-Rasmussen U., Nielsen R. (2007) Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice. J. Am. Soc. Nephrol. 18, 698–706 [DOI] [PubMed] [Google Scholar]
- 6.Burkholder P. M., Updike S. J., Ware R. A., Reese O. G. (1980) Clinicopathologic, enzymatic, and genetic features in a case of Fabry’s disease. Arch. Pathol. Lab. Med. 104, 17–25 [PubMed] [Google Scholar]
- 7.Najafian B., Svarstad E., Bostad L., Gubler M. C., Tøndel C., Whitley C., Mauer M. (2011) Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int. 79, 663–670 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Desnick R. J., Yiannis A., Ioannou Y. A., Eng C. M. (2001) α-Galactosidase a deficiency: Fabry disease. In The Metabolic & Molecular Bases of Inherited Disease, 8th ed. (Scriver C. R., Beaudet A. L., and Sly W. S., eds.), pp. 3733–3774, McGraw-Hill, New York [Google Scholar]
- 9.Sessa A., Meroni M., Battini G., Righetti M., Nebuloni M., Tosoni A., Vago G. L.; Studio Multicentrico Italiano Sulla Malattia di Anderson–Fabry (2003) Evolution of renal pathology in Fabry disease. Acta Paediatr. Suppl. 92, 6–8, discussion 5 [DOI] [PubMed] [Google Scholar]
- 10.Alroy J., Sabnis S., Kopp J. B. (2002) Renal pathology in Fabry disease. J. Am. Soc. Nephrol. 13(Suppl 2), S134–S138 [PubMed] [Google Scholar]
- 11.Fogo A. B., Bostad L., Svarstad E., Cook W. J., Moll S., Barbey F., Geldenhuys L., West M., Ferluga D., Vujkovac B., Howie A. J., Burns A., Reeve R., Waldek S., Noël L. H., Grünfeld J. P., Valbuena C., Oliveira J. P., Müller J., Breunig F., Zhang X., Warnock D. G.; all Members of the International Study Group of Fabry Nephropathy (ISGFN) (2010) Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol. Dial. Transplant. 25, 2168–2177 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Colley J. R., Miller D. L., Hutt M. S., Wallace H. J., De Wardener H. E. (1958) The renal lesion in angiokeratoma corporis diffusum. Br. Med. J. 1, 1266–1268 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Parkinson J. E., Sunshine A. (1961) Angiokeratoma corporis diffusum universale (Fabry). Presenting as suspected myocardial infarction and pulmonary infarcts. Am. J. Med. 31, 951–958 [DOI] [PubMed] [Google Scholar]
- 14.Henry E. W., Rally C. R. (1963) The renal lesion in angiokeratoma corporis diffusum (Fabry’s disease). Can. Med. Assoc. J. 89, 206–213 [PMC free article] [PubMed] [Google Scholar]
- 15.Parchoux B., Guibaud P., Maire I., Bouvier R., Goddon R., Badinand P., Gueho A., Larbre F. (1978) Fabry’s disease. Initial nephrogenic diabetes insipidus in children. Pediatrie 33, 757–765 [PubMed] [Google Scholar]
- 16.Wornell P., Dyack S., Crocker J., Yu W., Acott P. (2006) Fabry disease and nephrogenic diabetes insipidus. Pediatr. Nephrol. 21, 1185–1188 [DOI] [PubMed] [Google Scholar]
- 17.Ohshima T., Schiffmann R., Murray G. J., Kopp J., Quirk J. M., Stahl S., Chan C. C., Zerfas P., Tao-Cheng J. H., Ward J. M., Brady R. O., Kulkarni A. B. (1999) Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc. Natl. Acad. Sci. USA 96, 6423–6427 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Ohshima T., Murray G. J., Swaim W. D., Longenecker G., Quirk J. M., Cardarelli C. O., Sugimoto Y., Pastan I., Gottesman M. M., Brady R. O., Kulkarni A. B. (1997) α-Galactosidase A deficient mice: a model of Fabry disease. Proc. Natl. Acad. Sci. USA 94, 2540–2544 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Valbuena C., Oliveira J. P., Carneiro F., Relvas S., Ganhão M., Sá-Miranda M. C., Rodrigues L. G. (2011) Kidney histologic alterations in α-Galactosidase–deficient mice. Virchows Arch. 458, 477–486 [DOI] [PubMed] [Google Scholar]
- 20.Taguchi A., Maruyama H., Nameta M., Yamamoto T., Matsuda J., Kulkarni A. B., Yoshioka H., Ishii S. (2013) A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis. Biochem. J. 456, 373–383 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Vylet’al P., Hůlková H., Zivná M., Berná L., Novák P., Elleder M., Kmoch S. (2008) Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell storage alteration and is reversible by enzyme replacement therapy. J. Inherit. Metab. Dis. 31, 508–517 [DOI] [PubMed] [Google Scholar]
- 22.Mount D. B. (2014) Thick ascending limb of the loop of Henle. Clin. J. Am. Soc. Nephrol. 9, 1974–1986 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Bhagat C. I., Garcia-Webb P., Fletcher E., Beilby J. P. (1984) Calculated vs measured plasma osmolalities revisited. Clin. Chem. 30, 1703–1705 [PubMed] [Google Scholar]
- 24.Kemter E., Rathkolb B., Bankir L., Schrewe A., Hans W., Landbrecht C., Klaften M., Ivandic B., Fuchs H., Gailus-Durner V., Hrabé de Angelis M., Wolf E., Wanke R., Aigner B. (2010) Mutation of the Na+-K+-2Cl- cotransporter NKCC2 in mice is associated with severe polyuria and a urea-selective concentrating defect without hyperreninemia. Am. J. Physiol. Renal Physiol. 298, F1405–F1415 [DOI] [PubMed] [Google Scholar]
- 25.Psotka M. A., Obata F., Kolling G. L., Gross L. K., Saleem M. A., Satchell S. C., Mathieson P. W., Obrig T. G. (2009) Shiga toxin 2 targets the murine renal collecting duct epithelium. Infect. Immun. 77, 959–969 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Askari H., Kaneski C. R., Semino-Mora C., Desai P., Ang A., Kleiner D. E., Perlee L. T., Quezado M., Spollen L. E., Wustman B. A., Schiffmann R. (2007) Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch. 451, 823–834 [DOI] [PubMed] [Google Scholar]
- 27.Ares G. R., Caceres P. S., Ortiz P. A. (2011) Molecular regulation of NKCC2 in the thick ascending limb. Am. J. Physiol. Renal Physiol. 301, F1143–F1159 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kone B. C., Madsen K. M., Tisher C. C. (1984) Ultrastructure of the thick ascending limb of Henle in the rat kidney. Am. J. Anat. 171, 217–226 [DOI] [PubMed] [Google Scholar]
- 29.Mutig K., Kahl T., Saritas T., Godes M., Persson P., Bates J., Raffi H., Rampoldi L., Uchida S., Hille C., Dosche C., Kumar S., Castañeda-Bueno M., Gamba G., Bachmann S. (2011) Activation of the bumetanide-sensitive Na+,K+,2Cl- cotransporter (NKCC2) is facilitated by Tamm–Horsfall protein in a chloride-sensitive manner. J. Biol. Chem. 286, 30200–30210 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Katz A. I., Doucet A., Morel F. (1979) Na-K-ATPase activity along the rabbit, rat, and mouse nephron. Am. J. Physiol. 237, F114–F120 [DOI] [PubMed] [Google Scholar]
- 31.Weidemann F., Sanchez-Niño M. D., Politei J., Oliveira J. P., Wanner C., Warnock D. G., Ortiz A. (2013) Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J. Rare Dis. 8, 116 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Subramanya A. R., Ellison D. H. (2014) Distal convoluted tubule. Clin. J. Am. Soc. Nephrol. 9, 2147–2163 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Ellison D. H., Velázquez H., Wright F. S. (1989) Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. J. Clin. Invest. 83, 113–126 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Ellison D. H., Velázquez H., Wright F. S. (1987) Thiazide-sensitive sodium chloride cotransport in early distal tubule. Am. J. Physiol. 253, F546–F554 [DOI] [PubMed] [Google Scholar]
- 35.Moes A. D., van der Lubbe N., Zietse R., Loffing J., Hoorn E. J. (2014) The sodium chloride cotransporter SLC12A3: new roles in sodium, potassium, and blood pressure regulation. Pflugers Arch. 466, 107–118 [DOI] [PubMed] [Google Scholar]
- 36.Lalioti M. D., Zhang J., Volkman H. M., Kahle K. T., Hoffmann K. E., Toka H. R., Nelson-Williams C., Ellison D. H., Flavell R., Booth C. J., Lu Y., Geller D. S., Lifton R. P. (2006) Wnk4 controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. Nat. Genet. 38, 1124–1132 [DOI] [PubMed] [Google Scholar]
- 37.Fushimi K., Uchida S., Hara Y., Hirata Y., Marumo F., Sasaki S. (1993) Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 361, 549–552 [DOI] [PubMed] [Google Scholar]
- 38.Biancini G. B., Jacques C. E., Hammerschmidt T., de Souza H. M., Donida B., Deon M., Vairo F. P., Lourenço C. M., Giugliani R., Vargas C. R. (2016) Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy. Clin. Chim. Acta 461, 41–46 [DOI] [PubMed] [Google Scholar]
- 39.Clausen T., Van Hardeveld C., Everts M. E. (1991) Significance of cation transport in control of energy metabolism and thermogenesis. Physiol. Rev. 71, 733–774 [DOI] [PubMed] [Google Scholar]
- 40.Colvin R. B. (2015) Fabry disease. In Diagnostic Pathology: Kidney Diseases, 2nd ed. (Chang A., and Colvin R. B., eds.), pp. 416–423, Elsevier, Philadelphia [Google Scholar]
- 41.Tøndel C., Bostad L., Larsen K. K., Hirth A., Vikse B. E., Houge G., Svarstad E. (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J. Am. Soc. Nephrol. 24, 137–148 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Singh P., McDonough A. A., Thomson S. C. (2015) Metabolic basis of solute transport. In Brenner & Rector’s The Kidney, 10th ed. (Skorecki K., Chertow G. M., Marsden P. A., Taal M. W., and Yu A. S. L., eds.), pp. 122–143, Elsevier, Philadelphia [Google Scholar]
- 43.Munger K. A., Maddox D. A., Brenner B. M., Kost C. K., Jr (2015) The renal circulations and glomerular ultrafiltration. In Brenner & Rector’s The Kidney, 10th ed. (Skorecki K., Chertow G. M., Marsden P. A., Taal M. W., and Yu A. S. L., eds.), pp. 83–111, Elsevier, Philadelphia [Google Scholar]
- 44.Seyberth H. W., Schlingmann K. P. (2011) Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. Pediatr. Nephrol. 26, 1789–1802 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Mount D. B. (2015) Transport of sodium, chloride, and potassium. In Brenner & Rector’s The Kidney, 10th ed. (Skorecki K., Chertow G. M., Marsden P. A., Taal M. W., and Yu A. S. L., eds.), pp. 144–184, Elsevier, Philadelphia [Google Scholar]
- 46.Takahashi N., Chernavvsky D. R., Gomez R. A., Igarashi P., Gitelman H. J., Smithies O. (2000) Uncompensated polyuria in a mouse model of Bartter’s syndrome. Proc. Natl. Acad. Sci. USA 97, 5434–5439 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Bachmann S., Mutig K., Bates J., Welker P., Geist B., Gross V., Luft F. C., Alenina N., Bader M., Thiele B. J., Prasadan K., Raffi H. S., Kumar S. (2005) Renal effects of Tamm–Horsfall protein (uromodulin) deficiency in mice. Am. J. Physiol. Renal Physiol. 288, F559–F567 [DOI] [PubMed] [Google Scholar]
- 48.Labilloy A., Youker R. T., Bruns J. R., Kukic I., Kiselyov K., Halfter W., Finegold D., do Monte S. J., Weisz O. A. (2014) Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease. Mol. Genet. Metab. 111, 184–192 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Welker P., Böhlick A., Mutig K., Salanova M., Kahl T., Schlüter H., Blottner D., Ponce-Coria J., Gamba G., Bachmann S. (2008) Renal Na+-K+-Cl- cotransporter activity and vasopressin-induced trafficking are lipid raft-dependent. Am. J. Physiol. Renal Physiol. 295, F789–F802 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Welker P., Geist B., Frühauf J. H., Salanova M., Groneberg D. A., Krause E., Bachmann S. (2007) Role of lipid rafts in membrane delivery of renal epithelial Na+-K+-ATPase, thick ascending limb. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R1328–R1337 [DOI] [PubMed] [Google Scholar]
- 51.Feng M., Whitesall S., Zhang Y., Beibel M., D’Alecy L., DiPetrillo K. (2008) Validation of volume-pressure recording tail-cuff blood pressure measurements. Am. J. Hypertens. 21, 1288–1291 [DOI] [PubMed] [Google Scholar]
- 52.Hoorn E. J., McCormick J. A., Ellison D. H. (2011) High tail-cuff blood pressure in mice 1 week after shipping: the need for longer acclimation. Am. J. Hypertens. 24, 534–536 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.